U.S., March 19 -- ClinicalTrials.gov registry received information related to the study (NCT06880770) titled 'Study of Plozasiran in Adults With Severe Hypertriglyceridemia at Risk of Acute Pancreatitis' on March 12.
Brief Summary: This study will evaluate the efficacy and safety of plozasiran in approximately 140 adult participants with severe hypertriglyceridemia (SHTG) and history of at least two prior acute pancreatitis (AP) events not attributed to other etiologies, with at least one occurring within the last 12 months prior to screening. Eligible participants will be randomly assigned in a double-blind manner to either receive plozasiran 25 mg by subcutaneous (SC) injection every three months (Q3M) or matching placebo. Enrolled parti...